Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Unknown 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 64HER2-positive Breast Cancer 11Carcinoma, Non-Small-Cell Lung 6HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4HER2 Positive Breast Cancer 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2HER2-positive Metastatic Breast Cancer 2Colorectal Neoplasms 2Breast Cancer Invasive 2Breast Cancer Female 2Solid Tumor 1Salivary Gland Neoplasms 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non-squamous NSCLC 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-expressing Advanced Solid Tumors 1HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1HER2+ Early or Locally Advanced Breast Cancer 1

Interventions

exemestane 7Trastuzumab 7Anastrozole 7Letrozole 6Docetaxel 6palbociclib 5pyrotinib 4entinostat 4Fulvestrant 4Cyclophosphamide 4ribociclib 3abemaciclib 3Tamoxifen 3Doxorubicin 3pertuzumab 2Sodium Chloride 2Paclitaxel 2Lapatinib 2Gonadotropin-Releasing Hormone 2Exercise 2Everolimus 2Epirubicin 2Drug Evaluation 2Capecitabine 2Botulinum Toxins, Type A 2Aromatase Inhibitors 2AZD9833 2trastuzumab deruxtecan 1taxane 1sacubitril and valsartan sodium hydrate drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Breast Diseases × pyrotinib × Clear all
NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Sun Yat-sen University

Phase 2 Unknown
208 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Fuzhou General Hospital

Phase 2 Unknown
77 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT03756064 2019-08-13

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Zhejiang Cancer Hospital

Phase NA Unknown
100 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Peking Union Medical College Hospital

Phase 2 Unknown
250 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡